Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance on cabozantinib for untreated advanced renal cell carcinoma published

Published: 30 November 2018
NICE guidance issued

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of the drug cabozantinib (CABOMETYX®) for untreated advanced renal cell carcinoma, informed by a report produced by SHTAC.

NICE’s guidance recommends cabozantinib, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate‑ or poor‑risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria. It is recommended only if the company provides cabozantinib according to a commercial arrangement in which the drug is offered as part of a simple discount patient access scheme.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research on cancer into please visit our Research page.


Privacy Settings